There were 516 press releases posted in the last 24 hours and 185,326 in the last 365 days.

Pneumonia Vaccine Market Size To Reach USD 10.21 Billion, Globally, By 2025

Pneumonia Vaccine

Introduction of novel pneumococcal vaccines into the market is expected to boost the growth of the global pneumonia vaccine market.

The growth in global pneumonia vaccine market is due to increase in prevalence of pneumonia across the globe and rise in government focus on immunization programs for pneumonia.”
— Mangesh Panhale

According to the research report published by Allied Market Research, the global pneumonia vaccines market is expected to register a CAGR of 10.21% from 2018 to 2025. The research includes changing market dynamics, top impacting factors, key investment pockets, value chain, and competitive scenario. Through tabular and graphical representation, the report offers key insights on different aspects of the market such as current market size and estimations, region-wise analysis, and opportunities. Porter’s Five Forces analysis has been mentioned in the report to outline competitive intensity. The report is a helpful source of information to unlock potential from emerging countries and expand businesses to gain international presence.

Growing incidence of pneumonia globally, increased government focus on immunization programs for pneumonia, and rise in focus for new pneumococcal vaccines propel the market growth. However, longer timelines required for pneumonia vaccine production and high cost associated with the development of such vaccines restrain the growth of the market. Conversely, the development of protein-based combination pneumococcal vaccines creates new opportunities for the growth of the market.

To Get the Sample Copy of Report Visit @

Pneumococcal conjugate vaccine (PCV) segment to dominate through 2025

Among vaccine types, the pneumococcal conjugate vaccine (PCV) segment accounted for 89% of the overall market share in 2017 and would retain its dominance through 2025. This is because it is the most commonly used vaccine types among end users. However, the pneumococcal polysaccharide vaccine (PPV) segment would grow at the fastest CAGR of 5.4% during the forecast period. This is because these vaccines are less expensive than PCV and is popularly used in developing countries.

Prevnar 13 segment to be lucrative through 2025

Among product types, the Prevnar 13 segment was the largest in 2017, capturing 79.1% of the market share and would maintain its dominance through 2025. The segment would also grow at the fastest CAGR of 5.1% from 2018 to 2025. This is because it is one of the most efficient pneumonia vaccines adopted globally. The report also discusses Synflorix and Pneumovax23.

For Purchase Enquiry @

Private sector segment to lead the market through 2025

Among sectors, the private sector captured around 90% of the market share in 2017 and is likely to dominate the market through 2025. The same would achieve the fastest CAGR of 5.1% from 2018 to 2025. This is because major regions such as US and Europe commonly purchase pneumonia vaccine through private sector.

North America to maintain revenue lead, Asia Pacific to grow the fastest through 2025

The market in North America captured more than half of the market share in 2017 and is expected to dominate the market through 2025. This is due to wider pneumonia vaccination coverage in the region. However, the market in Asia Pacific would grow at a CAGR of 6.6% during the forecast period. This is due to growing efforts by UNICEF and WHO for improvement of pneumonia vaccine coverage and growing awareness of importance of pneumonia vaccines to prevent disease in the region. The other regions analyzed in the report include Europe and LAMEA (Latin America, Middle East, and Africa).

Access Full Report @

The Major Key Players Are:
Glaxosmithkline plc., LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited), SK Bioscience, and Walvax Biotechnology Co., Ltd.

Similar Reports:

BCG Vaccines Sales Market Analysis and Industry Forecast, 2027

Conjugate Vaccines Market Analysis and Industry Forecast, 2027

Pandemic Influenza Vaccine Market Analysis and Industry Forecast, 2027

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media: